All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Darier disease (DD), also known as keratosis follicularis, is a rare and severe autosomal dominant skin disease, estimated to affect 1 in 30 000 to 100 000 people \[[@pone.0186356.ref001], [@pone.0186356.ref002]\]. The disease is characterized by keratotic papules and malodorous plaques in seborrheic areas of the skin, which can lead to large, crusted plaques. The disease often emerges during childhood and continues throughout adolescence, and can negatively influence the quality of life \[[@pone.0186356.ref002]\]. Disease phenotype is highly variable; even when two family members are affected by the same variant, the clinical symptoms may be different \[[@pone.0186356.ref003]\], which makes genotype-phenotype correlations difficult to determine. UVB irradiation, heat, friction and infections in affected areas can further exacerbate symptoms \[[@pone.0186356.ref004]\]. Other non-dermatological symptoms of DD include psychiatric conditions, such as intellectual disability and bipolar disease \[[@pone.0186356.ref002], [@pone.0186356.ref005]\].

DD is caused by mutations in the *ATP2A2* gene, which encodes the sarco/endoplasmic reticulum calcium (Ca^2+^) -ATPase isoform 2 (SERCA2), a calcium pump in the endoplasmic reticulum (ER) \[[@pone.0186356.ref006]\]. The *ATP2A2* gene transcript has two isoforms (isoform a and b), and consists of 21 or 20 exons, respectively ([Fig 1](#pone.0186356.g001){ref-type="fig"}). Both SERCA2 isoforms have a phosphorylation (P), nucleotide-binding domain (N) and the actuator domain (A; [Fig 1](#pone.0186356.g001){ref-type="fig"}).

![The location of all published/reported *ATP2A2* variants (in both isoforms) and variants discovered in the current study associated with Darier disease.\
*ATP2A2* isoform a consists of 21 exons (top row), which encodes for 10 transmembrane domains (M1 --M10, second row), and it is expressed in cardiomyocytes and slow-tiwtch skeletal muscles. The *ATP2A2* isoform b consists of 20 exons (fourth row), which encodes for 11 transmembrane domains (M1 --M11, third row) and it is expressed in most tissue types \[[@pone.0186356.ref003]\]. Both isoforms have an actuator domain (A, orange boxes), phosphorylation domain (P, pink boxes), nucleotide binding domain (N, green boxes) and C-terminus (lime green boxes). All genetic variants are listed in either pale yellow (exon with variants discovered in this study) or blue boxes (exon with no variants from this study). Novel genetic variants found in this study are in bold and coloured red. Variants that were discovered in this study but were not novel are in bold only. Intronic variants are in italics. † indicates *ATP2A2* variants with different genetic changes, but resulted in the same amino acid change.](pone.0186356.g001){#pone.0186356.g001}

Currently, there are over 270 unique *ATP2A2* mutations associated with DD \[[@pone.0186356.ref007], [@pone.0186356.ref008]\], and there are no mutational hotspots. The genetic mutations are predominantly missense/nonsense mutations, followed by deletions, splice-site and insertion mutations. Studies have shown that mutations in the *ATP2A2* gene disrupt normal SERCA2 protein function and leads to impaired/loss of Ca^2+^ transport in the ER, which leads to decreased ER Ca^2+^ stores \[[@pone.0186356.ref009]--[@pone.0186356.ref014]\]. Ca^2+^ imbalance affects cell-to-cell adhesion in skin and this could explain the DD skin phenotype \[[@pone.0186356.ref015]\].

To date, there has been no successful genotype-phenotype correlation established in DD. However, this could be important for the diagnosis of disease severity prediction and prognosis of patients. While an epidemiological study of intellectual disability and cognitive ability in Swedish DD patients have been conducted \[[@pone.0186356.ref016]\], the genetic aspect and the genotype-phenotype association have not been investigated in Sweden. In the current study, the coding sequence of *ATP2A2* of a cohort of 28 clinically diagnosed Swedish DD patients was screened using whole exome sequencing (WES). Patients were asked to score their disease severity and treatment efficacy. The genotype-phenotype association was also examined for all variants in relation to the patient's disease severity score.

Methods {#sec002}
=======

Patient recruitment {#sec003}
-------------------

Twenty-eight patients with clinically diagnosed DD were recruited from the Dermato-Venereology clinic of Karolinska University Hospital and other Dermato-Venereology clinics in Sweden, including Uppsala, Linköping and Uddevalla. All patients were Caucasian.

Ethical disclosure {#sec004}
------------------

All patients (and/or patients' guardians) gave written informed consent for genetic testing.

This study was approved by the Stockholm regional ethical board (2017/1098-32).

Patient questionnaire and determination of total body surface area {#sec005}
------------------------------------------------------------------

A questionnaire based on the study conducted by Burge and Wilkinson, (1992) \[[@pone.0186356.ref002]\] was issued to the patient cohort. The questions included the age of disease onset, the type of medication currently taken, the medication effect (ranked 1--5), disease severity (mild/moderate/severe and ranked from 1--5), general skin symptoms, quality of life, and factors that worsen disease (heat/friction/menstruation/pregnancy/stress/sun). The scores from 1--5 correspond to the following: 1, bad; 2, acceptable; 3, good; 4, very good; and 5, excellent \[[@pone.0186356.ref017]\].

The total body surface area (TBSA) affected by disease was assessed for each patient using photographs taken at the time when blood was drawn for WES. The TBSA was based on the rule of nines, which is a method used to quantify the area of affected skin in burns victims \[[@pone.0186356.ref018]\]. The assessment was blinded in that the genotype was unknown to the examiner.

Whole exome sequencing and bioinformatics analysis {#sec006}
--------------------------------------------------

The Centre of Genomics and Transcriptomics (CeGAT, Tubingen, Germany) performed the WES. The exome was enriched by the Agilent SureSelectXT Human All Exon V6 (Agilent, CA, USA). The enriched libraries were sequenced using the Illumina HiSeq (Illumina, CA, USA) high-throughput sequencing platform with a read-length of 2 x 100 bp. Raw sequencing reads were processed according to the CeGAT bioinformatics streamlined process to generate a list of *ATP2A2* gene variants.

Bidirectional Sanger-based sequencing confirmation {#sec007}
--------------------------------------------------

All reported *ATP2A2* variants were confirmed by bi-directional Sanger-based sequencing. All *ATP2A2* PCR primers were previously published by Ringpfeil et al., (2001) \[[@pone.0186356.ref019]\], with the addition of M13 forward or reverse sequences on the 5' end. PCR was performed as previously described \[[@pone.0186356.ref020]\]. PCR products were electrophoresed in 1% UltraPure^™^ Agarose (Thermo Fisher Scientific, MA, USA) with GelRed^™^ (Biotium, CA, USA) incorporated into the gel.

Subsequent to gel electrophoresis confirmation, the PCR products were submitted to KI Gene (Centre for Molecular Medicine, Karolinska University Hospital Solna, Sweden) for bi-directional Sanger-based sequencing. The sequence analysis was performed using Geneious software (version 7.1.9) \[[@pone.0186356.ref021]\].

*ATP2A2* variant analysis {#sec008}
-------------------------

The pathogenicity of missense and intronic/splice-site variants were assessed using *in silico* prediction programs. Missense variants were assessed with PolyPhen-2 \[[@pone.0186356.ref022]\], SIFT \[[@pone.0186356.ref023]\] and SNPs&GO \[[@pone.0186356.ref024]\], and the splice-site variants were assessed with ASSP \[[@pone.0186356.ref025]\] and HSF \[[@pone.0186356.ref026]\]. A mutation is categorised as benign or pathogenic when the majority of scores from the prediction programs are concordant \[[@pone.0186356.ref027]\]. For nonsense and frameshift mutations, it was assumed that the variants would be deleterious to correct protein function. The variants were not categorised solely based on the predicted outcomes; dbSNP database (build 149) \[[@pone.0186356.ref028]\], Exome Aggregation Consortium (ExAC) database \[[@pone.0186356.ref029]\], and Exome Sequencing Project (ESP) \[[@pone.0186356.ref030]\] database were also used to determine if variants were rare polymorphisms.

Results {#sec009}
=======

Twenty-eight patients (19 females and nine males) with clinically diagnosed DD were screened for *ATP2A2* variants. Nine were family members from four different families ([Table 1](#pone.0186356.t001){ref-type="table"}). Fourteen of the 28 patients have a family history of DD, nine could be sporadic cases and two patients were adopted ([Table 1](#pone.0186356.t001){ref-type="table"}). Twenty-one different variants were found, and 15 were novel variants that have not been previously reported in the literature or any databases (i.e. dbSNP \[[@pone.0186356.ref028]\] or LOVD database \[[@pone.0186356.ref007], [@pone.0186356.ref008]\]; [Table 1](#pone.0186356.t001){ref-type="table"} and [Fig 1](#pone.0186356.g001){ref-type="fig"}).

10.1371/journal.pone.0186356.t001

###### List of *ATP2A2* mutations found in DD patients described in this study.

![](pone.0186356.t001){#pone.0186356.t001g}

  ID                                          Age of testing                                     Age of onset   Sex   Family history of disease   Nucleotide change     Amino acid change                                 Zygosity         Exon                Domain                       Mutation type           dbSNP         ExAC/ESP        Predicted outcome   Reported
  ------------------------------------------- -------------------------------------------------- -------------- ----- --------------------------- --------------------- ------------------------------------------------- ---------------- ------------------- ---------------------------- ----------------------- ------------- --------------- ------------------- ----------------------------
  1                                           43                                                                F                                                                                                                                                                                                                                                     
  2                                           27                                                 11             M     Yes                         c.2840T\>G            p.L947R                                           Het              19                  M 9                          Missense                                              Pathogenic          
  3                                           50                                                 19             F     No                                                                                                                                                                                                                                              
  4                                           51                                                 14             M     No                          c.1762-3_1767del                                                        Het              14                  N                            Essential splice-site                                 Pathogenic          
  5[\*](#t001fn001){ref-type="table-fn"}      47                                                 19             M     No                          c.2172G\>A            p.A724=                                           Het              15                  P                            Synonymous              rs56243033    0.055/0.05      Benign              \[[@pone.0186356.ref031]\]
  6                                           56                                                 3.5            M     Yes                         c.2840T\>G            p.L947R                                           Het              19                  M 9                          Missense                                              Pathogenic          
  7[^†^](#t001fn001){ref-type="table-fn"}     68                                                 20             F     Yes                         c.1675C\>T            p.R559[\*](#t001fn001){ref-type="table-fn"}       Het              13                  N                            Nonsense                                              Pathogenic          
  8                                           67                                                 64             F     Adopted                     c.220-18G\>A                                                            Het              i3                  M 1                          Intronic                rs35235621    0.015/0.018     Benign              
  c.2843_2844delAT                            p.Y948Cfs[\*](#t001fn001){ref-type="table-fn"}33   Het            19    M 9                         Frameshift                                                                               Pathogenic                                                                                                                 
  9[^†^](#t001fn001){ref-type="table-fn"}     30                                                                M                                 c.1675C\>T            p.R559[\*](#t001fn001){ref-type="table-fn"}       Het              13                  N                            Nonsense                                              Pathogenic          
  c.2172G\>A                                  p.A724=                                            Het            15    P                           Synonymous            rs56243033                                        0.055/0.05       Benign              \[[@pone.0186356.ref031]\]                                                                             
  10                                          44                                                 14             F     Adopted                     c.1216C\>T            p.Q406[\*](#t001fn001){ref-type="table-fn"}       Het              10                  N                            Nonsense                                              Pathogenic          
  c.2172G\>A                                  p.A724=                                            Het            15    P                           Synonymous            rs56243033                                        0.055/0.05       Benign              \[[@pone.0186356.ref031]\]                                                                             
  11                                          60                                                 12             F     Yes                         c.2608-2A\>C                                                            Het              i17                                              Essential splice-site                                 Pathogenic          
  12                                          64                                                                F     Yes                         c.2608-2A\>C                                                            Het              i17                                              Essential splice-site                                 Pathogenic          
  13                                          78                                                 15             F     Yes                         c.803G\>T             p.C268F                                           Het              8                   M 3                          Missense                rs121912733                   Pathogenic          \[[@pone.0186356.ref003]\]
  c.1386_1390delTTCTA                         p.S463Nfs[\*](#t001fn001){ref-type="table-fn"}12   Het            11    N                           Frameshift                                                                               Pathogenic                                                                                                                 
  14                                          67                                                 16             M     Yes                         c.922_945del          p.P308_I315del                                    Het              8                   M 4                          Deletion (in-frame)                                   Likely pathogenic   
  15[\*\*](#t001fn001){ref-type="table-fn"}   65                                                 22.5           F     Yes                         c.79delG              p.E27Nfs[\*](#t001fn001){ref-type="table-fn"}27   Het              1                   A                            Frameshift                                            Pathogenic          
  16[\*\*](#t001fn001){ref-type="table-fn"}   44                                                 14             F     Yes                         c.79delG              p.E27Nfs[\*](#t001fn001){ref-type="table-fn"}27   Het              1                   A                            Frameshift                                            Pathogenic          
  17                                          60                                                 20             F     No                          c.2945C\>T            p.T982M                                           Het              20                  M 10                         Missense                rs149024535   0.0017/0.0003   Benign              \[[@pone.0186356.ref032]\]
  18                                          81                                                 Unsure         F     No                          c.2294C\>T            p.S765L                                           Het              15                  M 5                          Missense                                              Pathogenic          
  19                                          61                                                 16             F     No                          c.220-18G\>A                                                            Het              i3                  M 1                          Intronic                rs35235621    0.015/0.018     Benign              
  c.1825_1827delTCC                           p.S609del                                          Het            14    P                           Deletion (in-frame)   rs767885880                                       0.000008         Likely pathogenic                                                                                                          
  20                                          49                                                 13             F     No                          c.545-12C\>G                                                            Het              i6                  A                            Intronic                                              Benign              
  c.2797G\>A                                  p.V933M                                            Het            19    M 9                         Missense              rs372102705                                       0.0001/0.00008   Benign                                                                                                                     
  21                                          55                                                 14             F     Yes                         c.2385T\>G            p.N795K                                           Het              16                  M 6                          Missense                                              Pathogenic          
  22[\*](#t001fn001){ref-type="table-fn"}     48                                                 20             F     Yes                         c.1720G\>T            p.E574[\*](#t001fn001){ref-type="table-fn"}       Het              13                  N                            Nonsense                                              Pathogenic          
  c.2172G\>A                                  p.A724=                                            Het            15    P                           Synonymous            rs56243033                                        0.055/0.05       Benign              \[[@pone.0186356.ref031]\]                                                                             
  23[\*](#t001fn001){ref-type="table-fn"}     79                                                 23             F     Yes                         c.1720G\>T            p.E574[\*](#t001fn001){ref-type="table-fn"}       Het              13                  N                            Nonsense                                              Pathogenic          
  c.2172G\>A                                  p.A724=                                            Hom            15    P                           Synonymous            rs56243033                                        0.055/0.05       Benign              \[[@pone.0186356.ref031]\]                                                                             
  24                                          33                                                 22             F     Yes                         c.116A\>G             p.N39S                                            Het              1                   A                            Missense                                              Pathogenic          
  c.220-18G\>A                                                                                   Het            i3    M 1                         Intronic              rs35235621                                        0.015/0.018      Benign                                                                                                                     
  25                                          56                                                 15             M     No                                                                                                                                                                                                                                              
  26[^††^](#t001fn001){ref-type="table-fn"}   66                                                 16             F     Yes                         c.2272C\>T            p.Q758[\*](#t001fn001){ref-type="table-fn"}       Het              15                  M 5                          Nonsense                                              Pathogenic          
  27[^††^](#t001fn001){ref-type="table-fn"}   32                                                                M                                 c.2272C\>T            p.Q758[\*](#t001fn001){ref-type="table-fn"}       Het              15                  M 5                          Nonsense                                              Pathogenic          
  c.2172G\>A                                  p.A724=                                            Het            15    P                           Synonymous            rs56243033                                        0.055            Benign              \[[@pone.0186356.ref031]\]                                                                             
  28                                          61                                                 20             M     No                                                                                                                                                                                                                                              

\*^,\ †,^ \*\*^,\ ††^ represent patients that are related. Rows that are blank are patients who did not harbour an *ATP2A2* variant. F, female; M, male; Het, heterozygous; Hom, homozygous; i*x*, intron *x*; M*x*, transmembrane domain *x*; A, actuator domain; P, phosphorylation domain; N, nucleotide binding domain.

Four patients (patients 1, 3, 25 and 28) did not have any variants in the *ATP2A2* gene despite clinically diagnosed with DD, and two patients had benign *ATP2A2* variants (patient 5 and 17, [Table 1](#pone.0186356.t001){ref-type="table"}). Ten patients had two different *ATP2A2* variants, and for most of these patients, one variant was benign and the other predicted to be pathogenic ([Table 1](#pone.0186356.t001){ref-type="table"}). One patient had two benign variants (Patient 20), and one patient had two pathogenic variants (Patient 13; [Table 1](#pone.0186356.t001){ref-type="table"}). The read-depth of each of the *ATP2A2* exons for each patient sample is shown in [S1 Fig](#pone.0186356.s001){ref-type="supplementary-material"}.

Spectrum of variants {#sec010}
--------------------

Sixteen of 21 variants were predicted to be pathogenic ([Table 1](#pone.0186356.t001){ref-type="table"} and [S1](#pone.0186356.s003){ref-type="supplementary-material"} and [S2](#pone.0186356.s004){ref-type="supplementary-material"} Tables). There are five missense mutations; two in-frame deletions; two essential splice-site mutations; three frameshift mutations and four nonsense mutations ([Table 1](#pone.0186356.t001){ref-type="table"}). The benign variants consisted of two intronic mutations, two missense mutations, and one synonymous mutation ([Table 1](#pone.0186356.t001){ref-type="table"}). All variants are scattered throughout *ATP2A2* and these are shown in [Fig 1](#pone.0186356.g001){ref-type="fig"} in relation to all previously reported *ATP2A2* variants \[[@pone.0186356.ref007], [@pone.0186356.ref008]\]. Eleven variants are located in the transmembrane domains (M1, M3, M4, M5--7, M9 and M10), three in the actuator (A) domain, five in the nucleotide binding (N) domain, and two in the phosphorylation (P) domain ([Table 1](#pone.0186356.t001){ref-type="table"}).

Phenotypic analysis {#sec011}
-------------------

To investigate whether there is a genotype-phenotype correlation, patients were asked a series of questions regarding their disease state. Twenty-five of the 28 patients (89%) responded, 18 women and seven men. Four of these patients did not harbour an *ATP2A2* genetic variant.

The age of onset for the majority of patients was below 20 years of age (76%; [Fig 2A](#pone.0186356.g002){ref-type="fig"}). The total body surface area (TBSA) affected by disease was also variable, with the majority of patients having disease on 1--20% of their bodies (84%; [Fig 2B](#pone.0186356.g002){ref-type="fig"}). The most commonly affected skin areas were the skin folds (56%) and trunk of the body (52%; [Table 2](#pone.0186356.t002){ref-type="table"}). Itchy skin (92%), heat, sun and stress (72--84%) were the most common exacerbating factor for many patients ([Fig 2C and 2D](#pone.0186356.g002){ref-type="fig"}). More than half of the patients who responded to the questionnaire (60%) were negatively affected by DD and found that it affected their life quality ([Table 2](#pone.0186356.t002){ref-type="table"}). Most patients were treated systemically with either acitretin or isotretionin (68%), and some were treated topically (24%; [Fig 2E](#pone.0186356.g002){ref-type="fig"}).

![Clinical characteristics of the cohort.\
Age of onset (A), total body surface area affected (B), skin symptoms (C), worsening factors (D) and medication type (E) in the patient cohort.](pone.0186356.g002){#pone.0186356.g002}

10.1371/journal.pone.0186356.t002

###### Patient clinical characteristics.

![](pone.0186356.t002){#pone.0186356.t002g}

  ID                                          Sex   Nucleotide change   Type of medication   TBSA (%)   Affected skin areas                                             Reduction in quality of life?   General skin symptoms   Factors that worsens disease
  ------------------------------------------- ----- ------------------- -------------------- ---------- --------------------------------------------------------------- ------------------------------- ----------------------- ------------------------------------------------------
  1                                           F                                                                                                                                                                                 
  2                                           M     c.2840T\>G          Moisturizer          18         Face, scalp, trunk, only mildly in skin folds, mild elsewhere   Yes                             Itch                    Friction, heat, friction, stress, sun
  3                                           F                         Topical                         Back, shoulders, trunk                                          No                              Itch                    Heat, sun
  4                                           M     c.1762-3_1767del    Acitretin            4          Face, scalp, trunk, only mildly in skin folds                   No                              Itch                    Heat, stress, sun
  5[\*](#t002fn001){ref-type="table-fn"}      M     c.2172G\>A          Topical              1          Trunk, shoulders, back                                          No                              Itch                    Heat, stress, sun
  6                                           M     c.2840T\>G          Acitretin            10         Back, shoulders, trunk                                          No                              Itch                    Stress
  7[^†^](#t002fn001){ref-type="table-fn"}     F     c.1675C\>T          Acitretin            1          Small defined area only on one side                             No                              Itch                    Heat, sun
  8                                           F     c.220-18G\>A        Acitretin            5          Trunk                                                           No                              NA                      Sun
  c.2843_2844delAT                                                                                                                                                                                                              
  9[^†^](#t002fn001){ref-type="table-fn"}     M     c.1675C\>T                                                                                                                                                                  
  c.2172G\>A                                                                                                                                                                                                                    
  10                                          F     c.1216C\>T          Isotretinoin         6          Trunk                                                           Yes                             Itch                    Heat, sun
  c.2172G\>A                                                                                                                                                                                                                    
  11                                          F     c.2608-2A\>C        Acitretin            17         Hands, feet                                                     Yes                             Itch, pain              Friction, heat, stress, sun
  12                                          F     c.2608-2A\>C        Acitretin            12         Face, folds, trunk                                              Yes                             Itch                    Friction, heat, stress, sun
  13                                          F     c.803G\>T           Acitretin            18         Face, hands, scalp                                              Yes                             Odour, pain             Friction, heat, menstruation, pregnancy, stress, sun
  c.1386_1390delTTCTA                                                                                                                                                                                                           
  14                                          M     c.922_945del        Acitretin            14         Folds, only mild elsewhere                                      No                              Itch                    Heat, stress, sun
  15[\*\*](#t002fn001){ref-type="table-fn"}   F     c.79delG            None                 2          Folds, only mild elsewhere                                      Yes                             Itch, odour, pain       Friction, heat, stress, sun
  16[\*\*](#t002fn001){ref-type="table-fn"}   F     c.79delG            Acitretin            12         Entire body                                                     Yes                             Itch, odour, pain       Friction, heat, stress
  17                                          F     c.2945C\>T          Laser                1          Face, scalp, trunk, only mildly in skin folds                   Yes                             Itch, odour             Heat
  18                                          F     c.2294C\>T          Acitretin            12         Lower back, knee folds, waist                                   No                              Itch                    Heat
  19                                          F     c.220-18G\>A        Acitretin            6          Back, hands, feet, thighs, trunk                                Yes                             Itch, odour, pain       Heat, stress, sun
  c.1825_1827delTCC                                                                                                                                                                                                             
  20                                          F     c.545-12C\>G        Acitretin            10         Face, scalp, trunk, only mildly in skin folds                   Yes                             Itch, pain              Friction, heat, menstruation, stress
  c.2797G\>A                                                                                                                                                                                                                    
  21                                          F     c.2385T\>G          Acitretin            22         Entire body, also pharynx                                       Yes                             Itch, odour, pain       Friction, heat, stress, sun
  22[\*](#t002fn001){ref-type="table-fn"}     F     c.1720G\>T          Isotretinoin         20         Folds, mild elsewhere                                           No                              Itch                    Heat, stress, sun
  c.2172G\>A                                                                                                                                                                                                                    
  23[\*](#t002fn001){ref-type="table-fn"}     F     c.1720G\>T          Isotretinoin         25         Trunk                                                           No                              Itch                    Heat, stress, sun
  c.2172G\>A                                                                                                                                                                                                                    
  24                                          F     c.116A\>G           Topical              1          Face, genital area, hands                                       Yes                             Itch, odour, pain       Menstruation, stress
  c.220-18G\>A                                                                                                                                                                                                                  
  25                                          M                         Acitretin            38         Face, scalp, trunk, only mildly in skin folds                   Yes                             Itch                    Friction, stress, sun
  26[^††^](#t002fn001){ref-type="table-fn"}   F     c.2272C\>T          Topical              2          Trunk, only mildly in skin folds, mild elsewhere                Yes                             Itch, odour             Heat, sun
  27[^††^](#t002fn001){ref-type="table-fn"}   M     c.2272C\>T                                                                                                                                                                  
  c.2172G\>A                                                                                                                                                                                                                    
  28                                          M                         Topical              10         Scalp, trunk, only mildly in skin folds                         Yes                             Itch, pain              Friction, heat, friction, stress

\*^,\ †,^ \*\*^,\ ††^ represent patients that are related. Rows that are blank are patients who did not harbour an *ATP2A2* variant or they did not answer the questionnaire. TBSA, total body surface area; F, female; M, male; Het, heterozygous; Hom, homozygous; i*x*, intron *x*; M*x*, transmembrane domain *x*; A, actuator domain; P, phosphorylation domain; N, nucleotide binding domain.

Patients were asked to score the medication effect and disease severity ([Fig 3](#pone.0186356.g003){ref-type="fig"} and [S2 Fig](#pone.0186356.s002){ref-type="supplementary-material"}). Disease severity was scored in two different ways: whether disease was mild, moderate or severe; and ranked from 1--5 (1 corresponding to bad and 5 to excellent). Both medication effect and disease severity were analysed based on the *ATP2A2* variant and the protein domain location ([S2 Fig](#pone.0186356.s002){ref-type="supplementary-material"}), and the type of mutation (i.e. missense, frameshift, etc.; [Fig 3](#pone.0186356.g003){ref-type="fig"}).

![Medication effect (1--5), disease severity (mild--severe) and disease severity (1--5) scores sorted by mutation type.\
Medication effect and disease severity score (Top and bottom), a score of 1 = bad, 2 = acceptable, 3 = good, 4 = very good or 5 = excellent. Disease severity rate (Middle), a score of 1 = severe, 2 = moderate and 3 = mild. A score of 0 corresponds to patient's lack of answer to a particular category. The type of *ATP2A2* mutation is shown on the x-axis, and they are sorted into seven categories: No mutations, benign, missense, in-frame deletion, splice-site, frameshift and nonsense mutations. ● represent patients receiving systemic treatment; ▲represents patients receiving topical treatment; ◆ represent patients receiving no treatment and represent patients who have received laser treatment. The different coloured points represent the patients with two *ATP2A2* variants. Points with the same colours are variants in the same patient.](pone.0186356.g003){#pone.0186356.g003}

Patients treated systemically were more satisfied with medication effect (good to excellent scores) than topically treated patients, who scored their medication effect as bad to good ([Fig 3](#pone.0186356.g003){ref-type="fig"} and [S2 Fig](#pone.0186356.s002){ref-type="supplementary-material"}--top graphs). Genotype-negative patients scored their medication effects as bad to good, while benign variants scored medication effect as generally good ([Fig 3](#pone.0186356.g003){ref-type="fig"}, top graph). Medication effect for patients harbouring missense mutations were acceptable to very good regardless of treatment type ([Fig 3](#pone.0186356.g003){ref-type="fig"}, top graph). All patients with in-frame deletion, splice site, frameshift and nonsense mutations were systemically treated and ranked the medication effect at good to excellent ([Fig 3](#pone.0186356.g003){ref-type="fig"}, top graph).

The disease severity of genotype-negative patients or those with benign *ATP2A2* variants were rated as moderate ([Fig 3](#pone.0186356.g003){ref-type="fig"}, middle graph). Many patients scored disease severity at 2 (using the 1--5 scoring system), which equated to acceptable ([Fig 3](#pone.0186356.g003){ref-type="fig"}, bottom graph). Missense and in-frame deletion mutations caused mild to moderate disease, which is similar to the scores of 2 to 3 (acceptable to good) in disease severity ([Fig 3](#pone.0186356.g003){ref-type="fig"}, middle and bottom graphs). Splice-site and frameshift mutations scores were contradictory between the two different ranking systems. The scores varied widely for patients with either type of mutations (mild to severe); however, the corresponding disease severity scores ranged from 1 to 3 (bad to good).

Discussion {#sec012}
==========

To date, no study has successfully correlated genotype to phenotype in DD. In the current study, we screened a Swedish cohort of 28 clinically diagnosed DD patients using WES and found 15 novel variants that have not been reported previously. We estimate that this cohort comprises more than 10% of DD patients in Sweden. Genotype-phenotype correlation was investigated based on disease severity scores and failed to show mutations with specific clinical picture.

Genotypic results {#sec013}
-----------------

Twenty-one *ATP2A2* variants were identified in this study, 15 are novel variants that have not been previously reported. Sixteen of these variants are predicted to be pathogenic by *in silico* prediction programs. Despite the lack of functional studies investigating these variants, previous studies of different *ATP2A2* mutants (missense, nonsense and deletion mutations) showed that they all affect SERCA2 function by either decreasing protein expression, Ca^2+^-ATPase activity, Ca^2+^ transport or alter protein kinetic properties \[[@pone.0186356.ref009]--[@pone.0186356.ref014]\]. There is also evidence that mutant SERCA2 protein is an initiator of ER stress that causes human epidermal keratinocytes to round up, detach and induce apoptosis \[[@pone.0186356.ref010]\]. From these previous studies, it could be concluded that the 16 pathogenic variants reported in this study are likely to affect SRECA2 protein function. The variants are also associated with clinical data.

There were ten patients who had two *ATP2A2* variants (one double pathogenic and one double benign variants). To the authors' best knowledge there has been no reported cases of patients harbouring two *ATP2A2* variants. Therefore, it is unknown whether the patient with two pathogenic variants have an additive effect on disease severity.

The four patients (14%) who are genotype-negative, but show skin symptoms could be wrongly diagnosed for DD. The number of genotype-negative patients in this study is similar to other reports in literature, which have a range of 7--33% of patients who are genotype-negative \[[@pone.0186356.ref008], [@pone.0186356.ref033]--[@pone.0186356.ref035]\]. Three of the four patients have rated their disease as moderately severe. The fact that no *ATP2A2* variants were detected by WES does not necessarily mean that there is no mutation in the gene. There could be large deletions/insertions or cryptic splice-sites present that could not be detected using WES and require other methods (i.e. comparative genomic hybridisation microarray--CGH arrays, or multiplex ligation-dependent probe amplification--MLPA) to detect the copy number changes. There is also the possibility that some variants are in the unscreened regions of the *ATP2A2* gene, such as the promoter regions, intronic regions or the 3' untranslated region, which could affect expression/or function of the SERCA2 protein.

Phenotypic/clinical results {#sec014}
---------------------------

The clinical features/symptoms of the current cohort are similar to previously described DD patients \[[@pone.0186356.ref002], [@pone.0186356.ref036]\], including age of onset, affected skin areas, skin symptoms and factors that exacerbate disease. The patients in this study are treated with either oral retinoids (acitretin or isotretinoin) or topical treatments, which are also typical for other DD patients \[[@pone.0186356.ref036]\]. Many patients have ranked the systemic treatment as effective against DD symptoms; however, the treatment is often not well tolerated and cannot be taken long term \[[@pone.0186356.ref002]\]. Like other reported DD cases, disease severity is varied \[[@pone.0186356.ref003], [@pone.0186356.ref019], [@pone.0186356.ref032], [@pone.0186356.ref035], [@pone.0186356.ref037]--[@pone.0186356.ref039]\]. Four patients in the current cohort ranked their disease as severe (16%), 18 as moderate (72%) and three as mild (12%, based on the disease severity rating results).

Genotype-phenotype correlation {#sec015}
------------------------------

Similar to previous reports, establishing a cross-sectional genotype-phenotype correlation for DD was difficult \[[@pone.0186356.ref003], [@pone.0186356.ref019], [@pone.0186356.ref032], [@pone.0186356.ref035], [@pone.0186356.ref037]--[@pone.0186356.ref039]\]. Previous reports have shown that family members harbouring the same variant manifest different phenotypes \[[@pone.0186356.ref003]\], which was seen in the current study. Even when the *ATP2A2* variants were separated into protein region and mutation type (i.e. benign, missense, etc.), it was still difficult to find a correlation between genotype and phenotype. One possible reason could be that for a majority of *ATP2A2* variants, SERCA2 protein function is affected independent of the type or location of the mutation \[[@pone.0186356.ref009]--[@pone.0186356.ref014]\]. It could also be due to the variability of disease symptoms over time, which is influenced by environmental factors.

It is interesting to note that patients with only benign variants have moderate DD symptoms. Whether these variants have an effect on SERCA2 protein function is unknown, as none have been characterised. It is also possible that these patients could be DD phenocopies (non-genetic forms of the disease); however, Berg and Basset (1993) suggest the likelihood of this is rare \[[@pone.0186356.ref040]\]. This is because DD is a rare disease that is clearly inherited in an autosomal dominant manner \[[@pone.0186356.ref040]\]. There is also the possibility that the patients could harbour a second undetected *ATP2A2* variant (i.e. large deletion/insertion).

Limitations {#sec016}
-----------

Currently, DD is diagnosed by its appearance and histopathology. There are some dermatological diseases that may also resemble DD. We believe that this "crude" non-molecular diagnostic method will be supported with genetic testing in the future to further confirm the clinical diagnosis. As well as analytical limitations that may not be detecting all DD variants, patients may be wrongly diagnosed with DD as their symptoms resemble DD, which confounds result interpretation. Other limitations of the study is that patients determined the medication efficacy and disease severity, and there will be variability in how these two factors were determined between patients. As the study only examined cross-sectional disease severity a longer and larger multicentre prospective study to investigate disease severity may be a better method of determining this factor.

Conclusion {#sec017}
==========

Despite being unable to establish a genotype-phenotype correlation as the disease severity is variable amongst patients, we identified 15 novel variants that have not been previously reported in DD. This study is the first to use WES to screen DD patients, and it is the first to investigate the genetic aspect in Swedish DD patients.

Supporting information {#sec018}
======================

###### The read-depth of all *ATP2A2* exons from all patient samples.

An x represents each patient sample and yellow circles represent patients who are genotype-negative. The red bars show the median and 95% confidence intervals.

(TIF)

###### 

Click here for additional data file.

###### The scores patients gave for medication effect (1--5), disease severity (mild--severe) and disease severity (1--5) sorted by protein regions.

Medication effect and disease severity score (Top and bottom), a score of 1 = bad, 2 = acceptable, 3 = good, 4 = very good or 5 = excellent. Disease severity rate (Middle), a score of 1 = severe, 2 = moderate and 3 = mild. A score of 0 corresponds to patient's lack of answer to a particular category. The type of *ATP2A2* mutation is shown on the x-axis, and they are sorted into protein domains. ● represent patients receiving systemic treatment; ▲ represents patients receiving topical treatment; ◆ represent patients receiving no treatment and represent patients who have received laser treatment.

(TIF)

###### 

Click here for additional data file.

###### Polyphen-2, SNPs&GO and SIFT predictions for novel missense variants found in this study.

(DOCX)

###### 

Click here for additional data file.

###### ASSP and Human Splicing Finder predictions for novel variants affecting splice sites found in this study.

(DOCX)

###### 

Click here for additional data file.
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